TFEB and renal cell carcinoma: In addition, IHC for MelanA is also an effective identification method, which is positive in 90 % and 60 % of TFEB-associated renal cell carcinomas and TFEB-amplified renal cell carcinomas, respectively.[10] Another differential point is epithelioid angiomyolipoma, both of which show significant IHC overlap, consistently label melanocyte markers and cathepsin K, usually label CD117 and vimentin.